Protagonist Common Stock vs Net Tangible Assets Analysis

PTGX Stock

USD 29.98 0.43 1.41%

Protagonist Therapeutics financial indicator trend analysis is much more than just breaking down Protagonist Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagonist Therapeutics is a good investment. Please check the relationship between Protagonist Therapeutics Common Stock and its Net Tangible Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Common Stock vs Net Tangible Assets

Common Stock vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagonist Therapeutics Common Stock account and Net Tangible Assets. At this time, the significance of the direction appears to have no relationship.

The correlation between Protagonist Therapeutics' Common Stock and Net Tangible Assets is 0.03. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Protagonist Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagonist Therapeutics' Common Stock and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Protagonist Therapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Common Stock i.e., Protagonist Therapeutics' Common Stock and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.03

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Common Stock

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Protagonist Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Enterprise Value is likely to rise to about 1.2 B in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	443K	4.1M	12.9M	13.6M
Net Interest Income	443K	4.1M	12.9M	13.6M

Interest Income Net Interest Income

Protagonist Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Common Stock
Total Assets		0.81	0.83	-0.25	-0.04	0.99	0.72	-0.87	-0.85	0.39	0.87	0.52	0.25	1.0	0.62	0.94	0.96	0.23	-0.03	0.46	0.42	0.3	-0.8	0.87	1.0	0.1
Other Current Liab	0.81		0.61	-0.36	-0.49	0.87	0.45	-0.75	-0.69	0.29	0.73	0.32	-0.19	0.82	0.26	0.78	0.78	0.33	0.08	0.25	0.22	0.37	-0.57	0.69	0.82	0.09
Total Current Liabilities	0.83	0.61		-0.45	0.2	0.83	0.77	-0.69	-0.62	0.55	0.71	0.71	0.54	0.82	0.51	0.73	0.79	0.21	0.11	0.18	0.11	0.29	-0.69	0.72	0.82	0.21
Total Stockholder Equity	-0.25	-0.36	-0.45		-0.16	-0.35	-0.52	-0.09	0.0	-0.57	0.09	-0.58	-0.26	-0.24	0.43	-0.24	-0.32	-0.56	-0.67	0.69	0.71	-0.59	0.22	-0.39	-0.24	-0.01
Other Liab	-0.04	-0.49	0.2	-0.16		-0.12	0.49	0.28	0.05	0.19	-0.22	0.24	0.81	-0.07	0.21	-0.01	0.05	-0.05	0.31	-0.12	-0.15	-0.03	-0.24	0.22	-0.05	0.08
Net Tangible Assets	0.99	0.87	0.83	-0.35	-0.12		0.7	-0.84	-0.81	0.44	0.83	0.56	0.2	0.99	0.52	0.91	0.96	0.28	0.02	0.36	0.32	0.34	-0.77	0.84	0.98	0.03
Property Plant And Equipment Net	0.72	0.45	0.77	-0.52	0.49	0.7		-0.41	-0.59	0.41	0.46	0.54	0.55	0.7	0.39	0.68	0.83	0.26	0.44	0.08	0.04	0.32	-0.75	0.86	0.71	0.19
Net Debt	-0.87	-0.75	-0.69	-0.09	0.28	-0.84	-0.41		0.91	-0.26	-1.0	-0.3	-0.07	-0.87	-0.72	-0.86	-0.74	-0.23	0.39	-0.73	-0.69	-0.28	0.71	-0.66	-0.87	-0.19
Retained Earnings	-0.85	-0.69	-0.62	0.0	0.05	-0.81	-0.59	0.91		-0.25	-0.92	-0.28	-0.14	-0.86	-0.7	-0.92	-0.8	-0.41	0.24	-0.72	-0.69	-0.45	0.84	-0.85	-0.86	-0.17
Accounts Payable	0.39	0.29	0.55	-0.57	0.19	0.44	0.41	-0.26	-0.25		0.26	0.38	0.64	0.39	0.19	0.4	0.37	0.38	0.35	-0.2	-0.23	0.42	-0.62	0.32	0.39	0.08
Cash	0.87	0.73	0.71	0.09	-0.22	0.83	0.46	-1.0	-0.92	0.26		0.31	0.12	0.87	0.76	0.86	0.76	0.22	-0.37	0.74	0.7	0.27	-0.74	0.69	0.87	0.2
Non Current Assets Total	0.52	0.32	0.71	-0.58	0.24	0.56	0.54	-0.3	-0.28	0.38	0.31		0.36	0.51	0.09	0.39	0.5	0.37	-0.06	-0.14	-0.16	0.42	-0.25	0.44	0.49	-0.36
Other Assets	0.25	-0.19	0.54	-0.26	0.81	0.2	0.55	-0.07	-0.14	0.64	0.12	0.36		0.23	0.45	0.25	0.27	-0.02	0.28	-0.04	-0.09	0.03	-0.54	0.31	0.24	0.17
Cash And Short Term Investments	1.0	0.82	0.82	-0.24	-0.07	0.99	0.7	-0.87	-0.86	0.39	0.87	0.51	0.23		0.61	0.94	0.96	0.24	-0.04	0.46	0.42	0.3	-0.79	0.86	1.0	0.1
Net Receivables	0.62	0.26	0.51	0.43	0.21	0.52	0.39	-0.72	-0.7	0.19	0.76	0.09	0.45	0.61		0.59	0.56	-0.24	-0.38	0.84	0.8	-0.2	-0.7	0.47	0.62	0.09
Common Stock Shares Outstanding	0.94	0.78	0.73	-0.24	-0.01	0.91	0.68	-0.86	-0.92	0.4	0.86	0.39	0.25	0.94	0.59		0.88	0.43	-0.02	0.5	0.45	0.48	-0.86	0.92	0.95	0.24
Short Term Investments	0.96	0.78	0.79	-0.32	0.05	0.96	0.83	-0.74	-0.8	0.37	0.76	0.5	0.27	0.96	0.56	0.88		0.18	0.14	0.37	0.33	0.24	-0.8	0.9	0.96	0.05
Non Current Liabilities Total	0.23	0.33	0.21	-0.56	-0.05	0.28	0.26	-0.23	-0.41	0.38	0.22	0.37	-0.02	0.24	-0.24	0.43	0.18		0.07	-0.13	-0.12	1.0	-0.32	0.45	0.22	0.08
Inventory	-0.03	0.08	0.11	-0.67	0.31	0.02	0.44	0.39	0.24	0.35	-0.37	-0.06	0.28	-0.04	-0.38	-0.02	0.14	0.07		-0.66	-0.69	0.08	-0.16	0.21	-0.03	0.33
Other Current Assets	0.46	0.25	0.18	0.69	-0.12	0.36	0.08	-0.73	-0.72	-0.2	0.74	-0.14	-0.04	0.46	0.84	0.5	0.37	-0.13	-0.66		0.99	-0.12	-0.45	0.34	0.47	0.08
Other Stockholder Equity	0.42	0.22	0.11	0.71	-0.15	0.32	0.04	-0.69	-0.69	-0.23	0.7	-0.16	-0.09	0.42	0.8	0.45	0.33	-0.12	-0.69	0.99		-0.12	-0.41	0.29	0.43	-0.01
Total Liab	0.3	0.37	0.29	-0.59	-0.03	0.34	0.32	-0.28	-0.45	0.42	0.27	0.42	0.03	0.3	-0.2	0.48	0.24	1.0	0.08	-0.12	-0.12		-0.37	0.5	0.29	0.09
Long Term Investments	-0.8	-0.57	-0.69	0.22	-0.24	-0.77	-0.75	0.71	0.84	-0.62	-0.74	-0.25	-0.54	-0.79	-0.7	-0.86	-0.8	-0.32	-0.16	-0.45	-0.41	-0.37		-0.83	-0.8	-0.24
Property Plant And Equipment Gross	0.87	0.69	0.72	-0.39	0.22	0.84	0.86	-0.66	-0.85	0.32	0.69	0.44	0.31	0.86	0.47	0.92	0.9	0.45	0.21	0.34	0.29	0.5	-0.83		0.87	0.21
Total Current Assets	1.0	0.82	0.82	-0.24	-0.05	0.98	0.71	-0.87	-0.86	0.39	0.87	0.49	0.24	1.0	0.62	0.95	0.96	0.22	-0.03	0.47	0.43	0.29	-0.8	0.87		0.12
Common Stock	0.1	0.09	0.21	-0.01	0.08	0.03	0.19	-0.19	-0.17	0.08	0.2	-0.36	0.17	0.1	0.09	0.24	0.05	0.08	0.33	0.08	-0.01	0.09	-0.24	0.21	0.12

Click cells to compare fundamentals

Protagonist Therapeutics Account Relationship Matchups

Protagonist Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	154.9M	324.5M	347.7M	247.9M	358.0M	204.1M
Other Current Liab	(10.2M)	21.2M	38.6M	25.0M	19.4M	13.5M
Total Current Liabilities	35.4M	40.2M	44.0M	31.2M	21.3M	27.7M
Total Stockholder Equity	(217.7M)	(283.8M)	(409.4M)	(536.8M)	336.7M	353.5M
Net Tangible Assets	80.0M	279.6M	300.0M	215.6M	247.9M	141.3M
Property Plant And Equipment Net	7.7M	6.4M	6.7M	4.6M	2.1M	3.4M
Net Debt	(16.0M)	(111.4M)	(117.8M)	(122.1M)	(185.6M)	(176.3M)
Retained Earnings	(217.7M)	(283.8M)	(409.4M)	(536.8M)	(615.7M)	(584.9M)
Accounts Payable	2.8M	3.1M	1.6M	3.6M	772K	733.4K
Cash	33.0M	117.4M	123.7M	125.7M	186.7M	196.1M
Non Current Assets Total	9.6M	8.9M	7.0M	10.6M	2.4M	2.3M
Other Assets	450K	1.1M	1.9M	225K	258.8K	245.8K
Cash And Short Term Investments	133.0M	307.8M	326.9M	237.4M	341.6M	191.4M
Net Receivables	6.8M	3.5M	4.4M	52K	10.3M	10.8M
Common Stock Shares Outstanding	25.9M	34.4M	46.3M	49.0M	56.8M	29.8M
Short Term Investments	100.0M	188.5M	203.2M	111.6M	154.9M	99.8M
Liabilities And Stockholders Equity	(142.7M)	(238.9M)	(361.7M)	247.9M	358.0M	375.8M
Non Current Liabilities Total	39.5M	4.6M	3.7M	784.7M	221K	210.0K
Inventory	4.8M	4.0M	8.5M	(94K)	(10.3M)	(9.8M)
Other Current Assets	744K	311K	975K	42K	14.0M	14.7M
Other Stockholder Equity	221K	(28K)	299K	359K	952.5M	1.0B
Total Liab	75.0M	44.9M	47.7M	784.7M	21.3M	20.2M
Property Plant And Equipment Gross	7.7M	6.4M	11.0M	9.9M	8.4M	5.1M
Total Current Assets	145.3M	315.6M	340.7M	237.4M	355.6M	196.9M
Accumulated Other Comprehensive Income	(221K)	28K	(299K)	(359K)	(105K)	(110.3K)
Property Plant Equipment	7.7M	1.5M	6.7M	1.6M	1.8M	2.5M
Capital Surpluse	297.8M	563.4M	709.7M	752.7M	865.6M	908.9M
Retained Earnings Total Equity	(217.7M)	(283.8M)	(409.4M)	(536.8M)	(483.1M)	(458.9M)
Current Deferred Revenue	41.5M	14.5M	1.6M	69K	3K	2.9K
Net Invested Capital	89.8M	279.6M	300.0M	215.6M	336.7M	228.6M
Net Working Capital	109.9M	275.4M	296.7M	211.9M	334.3M	227.5M
Short Term Debt	1.3M	1.5M	2.2M	2.5M	1.1M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether Protagonist Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protagonist Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protagonist Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protagonist Therapeutics Stock:

How To Invest In Protagonist

Details

Is Protagonist Stock a good investment?

Details

What is Protagonist Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Protagonist Stock analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments

Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

2.54

Revenue Per Share

5.308

Quarterly Revenue Growth

(1.00)

Return On Assets

0.2138

Return On Equity

0.4175

The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protagonist Common Stock vs Net Tangible Assets Analysis

Common Stock vs Net Tangible Assets

Common Stock vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Common Stock

Net Tangible Assets

Protagonist Therapeutics fundamental ratios Correlations

Protagonist Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protagonist Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Protagonist Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Net Tangible Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Net Tangible Assets

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Cash	- 0.92	Retained Earnings
Total Current Assets	- 0.87	Net Debt
Cash And Short Term Investments	- 0.87	Net Debt
Net Debt	- 0.87	Total Assets